19 June 2013
Keywords: pfizer, selects, r343, rigel, earns, 5m, milestone
Article | 22 May 2006
The USA's Rigel Pharmaceuticals says that R343, its novel small-molecule drug candidate, has been selected for advanced preclinical development
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 May 2006
18 June 2013
© 2013 thepharmaletter.com